Proven Efficacy and Safety

Hizentra is proven effective in both CIDP and PI

Please select an indication:

PI

CSL Behring has been a leading innovator in SCIg replacement therapy

Hizentra is the 1st SCIg approved:

  • With a 20% formulation in the US
  • For up to 2-week dosing*
  • For CIDP

Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older, and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

Frequently asked questions about Hizentra

Want to know more about Hizentra? See answers to many prescribers' frequently asked questions.

Frequently asked questions

Flexibility with Hizentra self-administration

Create personalized treatment plans to meet your patients' clinical needs and personal preferences.

See why Hizentra may be right for your patients
*Primary immunodeciency.
You are now leaving the current website.

Do you want to continue?

No Yes